Details

Autor(en) / Beteiligte

• Mohammadifard, Noushin
• Maghroun, Maryam
• Taheri, Marzie
• Mansourian, Marjan
• Najafi, Farid
• Farshidi, Hossein
• Kazemi, Toba
• Lotfizadeh, Masoud
• Solati, Kamal
• Pourmoghaddas, Ali
• Alikhasi, Hassan
• Najafian, Jamshid
• Sadeghi, Masoumeh
• Rabiei, Katayoun
• Roohafza, Hamidreza
• Sabri, Mahammadreza
• Sarrafzadegan, Nizal

Titel

Rationale, Design, and Initial Findings of Community Trial on Improving the Iranian's Knowledge and Practice of Dyslipidemia Management, Prevention, and Control

Ist Teil von

• ARYA atherosclerosis, 2022-12, Vol.18 (December), p.1-12

Ort / Verlag

Isfahan: Isfahan Cardiovascular Research Center

Erscheinungsjahr

2022

Quelle

Elektronische Zeitschriftenbibliothek - Freely accessible e-journals

Beschreibungen/Notizen

• The baseline of this national, multicentric community trial was conducted on three groups: the general population (adults over the age of 18 and their children aged 6-18), patients with dyslipidemia and their caregivers, and health professionals (physicians, nurses, health providers, and health workers). Keywords: : Knowledge, General Practice, Professional Practice, Hyperlipidemias, Dyslipidemias, Surveys Introduction Cardiovascular disease (CVD) has become a significant pandemic, particularly in developing countries such as Iran.1'2 Iran has one of the highest rates of age-standardized CVD prevalence.2 It has the potential to cause the greatest epidemic unless the trend is reversed by implementing cost-effective preventive strategies.3 The link between hypercholesterolemia and CVD has previously been well-documented.4 A recent meta-analysis found that lowering the low-density lipoprotein cholesterol (LDL-C) by one mmol/L reduces the risk of coronary heart disease (CHD) by 24% and stroke by 20%.5 Several surveys were conducted in most European countries to assess how well the lipids guidelines are implemented in clinical practice.6 However, large proportions of CHD patients continue to fall short of the lifestyles, risk factor levels, and therapeutic targets established by guidelines. Controlling dyslipidemia can result in cost savings due to fewer medications, primary care visits, and outpatient attendance. 7 Even when an effective, well-tolerated agent is prescribed, improving adherence to therapy necessitates educating patients, reminding and encouraging physicians, and developing new medication administration methods.8 Dyslipidemia was found in 66.3% of adults and 23.7% of children in Iran.9-10 While the awareness level is 14.4%,u developing extensive multidisciplinary intervention programs to raise dyslipidemia awareness among the population is critical for public hp^lth AsiHp from pnrnnramno- nVivsirmns Materials and Methods Study design The LIPOKAP study was a community-based multicenter trial conducted in three stages: baseline, intervention, and post-intervention. Participants Different approaches were used to select three target populations: the general population (adults and their children, and adolescents), patients with dyslipidemia and their caregivers, and health professionals (physicians, health care providers, health care workers, and nurses) were chosen by a different approach.